The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992.
 
Arjun Vasant Balar
Honoraria - AstraZeneca/MedImmune; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Cerulean Pharma; Dragonfly Therapeutics; Genentech/Roche; Incyte; Merck; Nektar; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen
 
Nicholas D. James
Honoraria - Astellas Pharma; Bayer; Janssen; Oncogenex; Pierre Fabre; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Clovis Oncology; EUSA pharma; Janssen; pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; Ferring; Janssen Oncology; Pierre Fabre; Sanofi
Research Funding - Astellas Pharma (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Janssen; Sanofi
 
Shahrokh F. Shariat
Stock and Other Ownership Interests - Seagen; Urogen pharma
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Cepheid; Dr. August Wolff GmbH & Co. KG Arzneimittel; Ferring; Ipsen; Janssen; MSD; Olympus; Pfizer; Pierre Fabre; Roche; Sanochemia; Sanofi; Urogen pharma
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; Ipsen; Janssen; Lilly; MSD; Olympus; Pfizer; Pierre Fabre; Ribon Therapeutics; Roche; Sanochemia; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; Ipsen; Janssen; Lilly; MSD; Olympus; Pfizer; Pierre Fabre; Ribon Therapeutics; Roche; Sanochemia; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent US07759077; Patent US20030054419; Patent US20030235816; Patent US2003235816
 
Neal D. Shore
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Merck; Myovant Sciences; Pfizer; Tolmar
Speakers' Bureau - Bayer; Dendreon; Janssen
 
Michiel Simon Van Der Heijden
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD Oncology (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Roche
 
Andrew James Weickhardt
Honoraria - Eisai; Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme
Speakers' Bureau - Astellas Pharma
Research Funding - Merck
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Merck Sharp & Dohme
 
Xiao Fang
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
James Luke Godwin
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Ekta Kapadia
Employment - Merck
 
Jeff M. Michalski
Stock and Other Ownership Interests - ViewRay (I)
Consulting or Advisory Role - Augmenix; Boston Scientific; Merck Sharp & Dohme; Mevion Medical Systems
Travel, Accommodations, Expenses - Augmenix; Boston Scientific; Merck Sharp & Dohme; Mevion Medical Systems